Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05203510 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Study acronym: ARTISAN
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 9, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv29
  2. Start date: Aug 10, 2022 to Oct 20, 2022v28
  3. Enrollment target: estimated 50 to confirmed 52v27
  4. Trial status: Recruiting to Active, Not Recruiting Primary completion date: Dec 31, 2025 to Apr 30, 2026 · Completion date: Dec 31, 2027 to Apr 30, 2028 · Site details revised at 28 of 28 sitesv26 Show 3 more changesShow less
    • Primary completion date: Dec 31, 2025 to Apr 30, 2026
    • Completion date: Dec 31, 2027 to Apr 30, 2028
    • Site details revised at 28 of 28 sites
  5. Site details revised at 2 of 28 sitesv25
Show 23 earlier versionsHide 23 earlier versions
  1. Site details revised at 1 of 28 sitesv24
  2. Site details revised at 1 of 28 sitesv23
  3. Site contacts updated at 1 of 28 sitesv22
  4. Study sites revised (28)v21 See this version in full on ClinicalTrials.gov ↗
  5. Site details revised at 1 of 28 sitesv20
  6. Primary completion date: Dec 31, 2024 to Dec 31, 2025 Site details revised at 1 of 28 sitesv19 Show 1 more changeShow less
    • Site details revised at 1 of 28 sites
  7. Study sites: 27 to 28v18
  8. Study sites: 25 to 27v17
  9. Primary completion date: Sep 12, 2024 to Dec 31, 2024 Completion date: Sep 12, 2024 to Dec 31, 2027v16 Show 1 more changeShow less
    • Completion date: Sep 12, 2024 to Dec 31, 2027
  10. Study sites: 24 to 25v15
  11. Study sites: 20 to 24v14
  12. Study sites: 19 to 20v13
  13. Study sites: 17 to 19v12
  14. Study sites: 15 to 17 Secondary endpoints revised (13) · Eligibility criteria expanded, about 2 wordsv11 Show 2 more changesShow less
    • Secondary endpoints revised (13)
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  15. Study sites: 11 to 15v10
  16. Study sites: 10 to 11v9
  17. Study sites: 7 to 10v8
  18. Study sites: 4 to 7 Eligibility criteria expanded, about 4 wordsv7 Show 1 more changeShow less
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  19. Study sites: 2 to 4v6
  20. Study sites: 1 to 2v5
  21. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Completion date: Sep 12, 2026 to Sep 12, 2024 · Start date changed from estimate of Aug 15, 2022 to Aug 10, 2022v4 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Completion date: Sep 12, 2026 to Sep 12, 2024
    • Start date changed from estimate of Aug 15, 2022 to Aug 10, 2022
  22. Start date: May 12, 2022 to Aug 15, 2022v3
  23. Start date: Feb 1, 2022 to May 12, 2022 Primary completion date: May 31, 2024 to Sep 12, 2024 · Completion date: May 31, 2026 to Sep 12, 2026 · Eligibility criteria revisedv2 Show 3 more changesShow less
    • Primary completion date: May 31, 2024 to Sep 12, 2024
    • Completion date: May 31, 2026 to Sep 12, 2026
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
United Therapeutics
13 trials monitored
See 2 trials at risk
Hypertension
1,795 trials monitored
See 85 trials at risk
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
Trial Details
NCT Number NCT05203510
Lead Sponsor United Therapeutics
Collaborators: Lung Biotechnology PBC
Conditions Pulmonary Arterial Hypertension
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov